Histamine, acting predominantly via the H 1 -receptor, is an important mediator of the symptoms of allergy, and H 1 -antihistamines, which stabilise the receptor in its inactive form, are the treatment of choice for some chronic allergic conditions. Ebastine is a well-established oral second-generation H 1 -antihistamine. It is administered once daily at a dose of 10-20 mg and is available as a standard tablet and also as a fast-dissolving tablet that disintegrates in the mouth. Ebastine has demonstrated to be efficacious at relieving symptoms in patients with allergic rhinitis or urticaria in multiple clinical trials. Ebastine has modulating effects on the allergic inflammatory process in addition to its antihistamine effects, which may help explain the beneficial effect it has on nasal obstruction in some patients. Ebastine is generally well tolerated at recommended doses and is one of the lowest-risk antihistamines with respect to adverse cognitive/psychomotor effects, confirmed after decades of pharmacovigilance. New long-term data confirm its efficacy and tolerability during up to 1 year of treatment in patients with chronic urticaria.
Introduction
Allergic disorders such as allergic rhinitis and urticaria are a common problem worldwide [1, 2] . Estimates of the prevalence of confirmed allergic rhinitis in Europe range from 17% to 28 .5% [1, 3] , and its prevalence is increasing in other countries with previous low to medium prevalence such as China and other geographic areas [1, [4] [5] [6] . The prevalence of urticaria is estimated to be 0.5-5% [2, [7] [8] [9] . In a cross-sectional population survey a lifetime prevalence for all types of urticaria was estimated to be approximately 9% and this was considered to be a lower limit because of conservative prevalence rate calculations employed [8] .
Both allergic rhinitis and urticaria have an adverse impact on quality of life and daily functioning [7, [10] [11] [12] [13] [14] , and allergic rhinitis, in particular, is associated with a high economic cost for society in terms of work absenteeism and presenteeism [15, 16] .
Histamine, acting predominantly via the H 1 -receptor, is an important mediator of the symptoms of allergy [17] ; histamine is released as a preformed mediator from activated mast cells during the early phase of the immune response [18] . H 1 -antihistamines, which stabilise the receptor in its inactive form, are a treatment of choice for allergic conditions [17] and they are included in international guidelines for the management of allergic rhinitis [1, 19] and urticaria [20] . Ebastine is a well-established second-generation H 1 -antihistamine [21] , available across Europe and worldwide for almost 30 years. The last comprehensive review of ebastine was published 10 years ago [21] . The current review summarises data on the use of ebastine to treat allergic rhinitis and urticaria, including new information that has become available in the last decade.
Allergic Rhinitis
Most clinical trials of ebastine in allergic rhinitis were conducted prior to the introduction of the ARIA classification based on intermittent or persistent symptoms, and therefore used the earlier terminology of seasonal and perennial allergic rhinitis. Studies generally enrolled adults and adolescents aged ≥12 years, and allergic rhinitis was usually diagnosed based on medical history and a positive skin prick test or IgE test. The most common primary efficacy parameter was the change from baseline in total symptom score; however, some studies used a global evaluation of symptomatic improvement/efficacy by the physician or patient.
The results of controlled trials of ebastine in adults/adolescents with seasonal allergic rhinitis or perennial allergic rhinitis are summarised in Tables 3 [54] [55] [56] [57] [58] [59] [60] [61] and 4 [62] [63] [64] [65] , respectively.
Ebastine was significantly more effective than placebo at relieving the symptoms of seasonal and perennial allergic rhinitis [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] .
The results of comparisons with other antihistamines indicate that ebastine 10 mg was at least as effective as cetirizine 10 mg and loratadine 10 mg at relieving the symptoms of allergic rhinitis, and ebastine 20 mg was generally more effective than loratadine 10 mg [58- 61, 64, 65] . A meta-analysis of four studies in seasonal allergic rhinitis confirmed that ebastine 20 mg was superior to loratadine 10 mg, as indicated by the mean change from baseline in the overall mean daily reflective total symptom score during the first 2 weeks of treatment (-3.61 [-35 .4%] versus -3.05 [-29 .0%], p<0.001) [66] . less effective for nasal congestion than for other nasal symptoms [1] . Three different studies that evaluated mean change from baseline in reflective and snapshot nasal congestion symptom scores (total of six scores across the three studies) found that ebastine 20 mg was more efficacious than placebo for six of six scores and ebastine 10 mg for four of six scores, whereas loratadine 10 mg was more efficacious than placebo for only one of six scores [70] .
A small non-comparative study in patients with persistent allergic rhinitis (n=20) that specifically evaluated nasal symptoms found that ebastine 20 mg significantly improved rhinomanometry-assessed nasal airflow by 59% from baseline (p=0.0001) and modified the response to the nasal decongestion test (p=0.0003) [71] .
Patient Acceptability and Satisfaction
It is important that therapies for allergic rhinitis are acceptable to patients, to help ensure that they adhere to long term treatments in the real-world setting. Studies evaluating patients' perception of the fast-dissolving tablet formulation of ebastine and their willingness to use it have been reviewed in detail previously [21, 72] . Patients generally preferred the taste and texture of the fast-dissolving tablet over the standard ebastine tablet [73] . Patients found that the fast-dissolving tablet was convenient and easy to use, perceived it to have a fast onset of action, and reported high levels of satisfaction with this formulation [73] [74] [75] [76] . Most expressed a preference for it over their previous antihistamine treatment [74] [75] [76] .
One of the patient preference studies, available only as a conference abstract for the last full review of ebastine, has since been published in full [76] . This international observational study of patients prescribed ebastine fast-dissolving tablet 20 mg within the previous 2 months (n=461), which used the Treatment Satisfaction Questionnaire for Medication (78.6) [76] . Compared with their previous antihistamine therapy, ebastine fast-dissolving tablet 20 mg was rated as better/much better by 81% of patients in terms of effectiveness, and by 73% for tolerability, 79% for onset of action and 94% for convenience. Overall, 94% of patients indicated they would like to continue using ebastine fast-dissolving tablet [76] .
Urticaria
The efficacy of ebastine in the treatment of chronic urticaria was evaluated in adult patients.
Ebastine was assessed in patients with chronic idiopathic urticaria (which would now be designated chronic spontaneous urticaria) in two randomised, double-blind, placebocontrolled trials [77, 78] , one of which also included a comparison with terfenadine [78] .
Ebastine 10 mg was significantly more efficacious than placebo at reducing the symptoms of urticaria and showed similar efficacy to terfenadine ( Table 5 ) [9, [77] [78] [79] [80] [81] [82] [83] [84] . More recently, a randomised trial with the primary aim of evaluating a method for predicting response to treatment in patients with chronic spontaneous urticaria (n=213), reported that all antihistamines evaluated (ebastine, bilastine, cetirizine, desloratadine, fexofenadine) provided similar efficacy in terms of symptom relief (assessed using the Urticaria Activity Score) and quality of life (Dermatology Life Quality Index) during 8 weeks of treatment ( Table 5 ) [9] .
In addition, efficacy data from two, previously unpublished, long-term, open-label studies of the safety and efficacy of ebastine in patients with chronic urticaria are available and are summarised here [80, 81] . These studies were both multicentre, open-label, noncomparative studies involving adults with chronic urticaria. Efficacy was evaluated through assessments of symptoms, including pruritus and number and size of wheals, and patient and physician J Investig Allergol Clin Immunol 2020; Vol. 30 (3) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0401 global evaluations. Both studies confirmed the long-term efficacy of ebastine 10 mg in this patient population.
In the first of these studies, 251 adults with chronic urticaria, from 11 centres in Spain, were enrolled into a 6-month, open-label, study evaluating the long-term safety and tolerability of ebastine 10 mg, in which efficacy was assessed as a secondary objective [80] . The primary evaluation was performed at 6 months. However, a subgroup of patients (n=58) continued into a second 6-month follow-up phase (i.e. total of 12 months). All symptoms (pruritus, number and size of wheals) improved significantly (p=0.0001) compared with baseline from month 1 (the first post-baseline visit) onwards and remained significantly improved at 6 months (Figure 1) . The percentage of patients with constant pruritus decreased from 23.9% at baseline to 4.8% after 6 months (Figure 1Aa) , while the percentage who had ≥16 wheals decreased from 47.0% to 13.2% (Figure 1Ab ) and the percentage who had wheals ≥30 mm in size decreased from 28.7% to 7.2% (Figure 1Ac ) (all p=0.0001). At 6 months, more than 70% of patients and physicians rated the overall efficacy of ebastine as optimum or good.
Significant differences (p=0.0001) from baseline in all symptoms were also seen at 12 months (Figures 1Ba,b ,c) in the subgroup that continued into the extension period.
The other long-term study evaluated the safety and efficacy of ebastine 10 mg in 192 adults with chronic urticaria enrolled from 36 centres across Europe [81] . Some patients entered this open-label study after participating in the trial that compared ebastine with terfenadine and placebo [78] , while others were enrolled de novo. Statistical comparisons versus baseline were not performed; however, there was a clear improvement in symptoms, including itching, the number of hours spent with symptoms, and wheal number and size, during the 12-month treatment period (Tables 5 and 6). The percentage of patients with severe itching decreased from 22.4% at baseline to <1% at 12 months, the mean number of hours spent with symptoms J Investig Allergol Clin Immunol 2020; Vol. 30 (3) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0401 of urticaria decreased from 38 to 6 hours per week, the percentage of patients with wheals of ≥30 mm in diameter decreased from 14.6% to 2.8%, and the percentage of patients with ≥16 wheals decreased from 27.1% to 5.6%. The overall evaluation of efficacy indicated that approximately 65% of both patients and physicians considered there had been a major improvement in symptoms during the study ( Tables 5 and 6 ).
The EAACI/GA 2 LEN/EDF/WAO guidelines on urticaria suggests that in patients with an inadequate response to standard doses of second-generation H 1 -antihistamines, the dose can be increased by up to four times the standard recommended dose [20] . The approved dose for ebastine in patients with urticaria is 10 mg. A small noncomparative study found that ebastine was well tolerated and effective at higher doses in patients with chronic spontaneous urticaria [79] (Table 5 ). Thirty patients were treated with ebastine for 4 weeks. The initial 10 mg dose could be increased after the first and second weeks in those patients with an inadequate response, to 20 mg and then 40 mg (administered as 10 mg or 20 mg twice daily). At the end of the first week, the dose was increased in 10 of 27 patients (3 patients were lost to followup). At the end of the second week the dose was increased again in 2 of these 10 patients.
Overall mean urticaria activity score decreased from 4.6 at baseline to 2.2 after 1 week, 1.1 after 2 weeks and <1.0 at 4 weeks, and 17, 8 and 2 patients became symptom-free on doses of 10, 20 and 40 mg, respectively. One patient reported mild sedation (at a dose of 40 mg) [79] .
Studies of ebastine in types of urticaria other than chronic idiopathic/spontaneous urticaria have generally used a dose of 20 mg ( Table 5 ). The results of two small, double-blind, crossover studies (n= 22 and n=7) suggested that ebastine 20 mg might be effective at preventing the symptoms of acquired cold urticaria [84] and dermographic urticaria [82] , including wheals, burning and itching. Recently, ebastine 20 mg was found to have similar efficacy to levocetirizine 5 mg, and to be more effective than ebastine 10 mg, in the treatment levocetirizine recipients and 50% of ebastine 10 mg recipients. The mean Urticaria Activity Scores in these groups at week 4 were 1.08, 1.98 and 3.98, respectively ( Table 5 ).
Safety and Tolerability
Ebastine 10-20 mg was generally well tolerated in clinical trials of 1-4 weeks' duration in patients with allergic rhinitis or urticaria: the incidence of adverse events with ebastine was similar to that for placebo, and most events were mild or moderate in severity [54,55,57,59-62,77]. The incidence of adverse events with ebastine was similar to that for active comparators such as loratadine and cetirizine [58- 60, 64, 65] . The most common adverse events with ebastine in placebo-controlled trials were headache (7.9%), drowsiness (3.0%) and dry mouth (2.1%) [21] .
Ebastine was found to have a favourable risk-benefit ratio with respect to sedation and had no However, no such increased risk was found in the other five databases, or in the overall pooled analysis involving a much larger number of cases/controls (2507/239,523) [95] .
Moreover, ebastine was not prescribed extensively in the countries covered by the study and only 8 cases and 680 controls were included in total. Pharmacovigilance data collected since ebastine was first introduced in 1989 have not resulted in any relevant change in the tolerability and safety texts of the approved summary of product characteristics after an estimated 65.5 million patients have received the original product.
Studies of 3-4 months' duration indicated that ebastine 10-20 mg was well tolerated in the longer term [57, 63, 78] . Data from two, previously unpublished, open-label studies in which ebastine 10 mg was administered to patients with chronic urticaria for up to 1 year confirmed that ebastine was well tolerated during long-term treatment [80, 81] .
In the first of these studies, in which the main aim was to evaluate safety and tolerability over a 6-month period (n=251), the percentage of patients reporting adverse events decreased over time, from 17.9% at 1 month to 7.2% at 6 months [80] . The most common adverse events reported at 1 month were drowsiness (4.6%), headache (3.7%) and gastralgia (2.0%). The most common adverse events reported at 6 months were drowsiness (2.0%), gastralgia (1.7%) and increased appetite (1.2%). At 6 months, 87.2% of physicians and 84.5% of patients J Investig Allergol Clin Immunol 2020; Vol. 30 (3) © 2019 Esmon Publicidad doi: 10.18176/jiaci.0401 considered the overall tolerability of ebastine to be 'good' (options: good, average, poor, not done). Among 58 patients who continued for an additional 6 months (i.e. total of 12 months), 8 .6% reported adverse events beyond 6 months, and 100% of physicians and patients reported overall tolerability as 'good' at 12 months.
The second long-term study in chronic urticaria evaluated the safety and tolerability of ebastine in 192 patients over a 12-month period [81] . Adverse events were reported for 59.4% of patients during the study period. Most were mild or moderate in severity. The most frequent treatment-related adverse events were weight gain (7.3%), increased appetite (5.2%), headache (4.7%), abdominal pain (4.7%), dry mouth (2.6%) and nervousness (2.6%). At the end of the study, physicians judged the overall tolerability of ebastine as 'good' for 87.3% of patients (options: good, fair, poor, not done).
Conclusion
Antihistamines are recommended by allergic rhinitis and urticaria guidelines [1, 19] . Because of their favourable efficacy/safety ratio, second-generation H 1 -antihistamines are recommended as first-line therapy for patients with allergic rhinitis/rhinoconjunctivitis or urticaria [1, 20, 94] .
Ebastine is a once-daily, oral, second-generation H 1 -antihistamine. The standard starting dose of 10 mg can be increased to 20 mg in patients with more severe or difficult-to-control symptoms. The availability of two formulations in a number of countries (a standard tablet and a fast-dissolving tablet that disintegrates in the mouth) provides patients with different options to suit their daily lives and preference. Ebastine has been demonstrated to be efficacious and well-tolerated in patients with allergic rhinitis or chronic urticaria in multiple clinical trials. The results of clinical trials published since the last in-depth review of ebastine support its efficacy and generally good tolerability when administered at recommended doses.
In particular, new long-term data confirm its efficacy and tolerability during up to 1 year of treatment in patients with chronic urticaria. Recent work has also confirmed that ebastine is one of the lowest-risk antihistamines in terms of cognitive/psychomotor effects. Ebastine was not associated with adverse cardiac effects in clinical trials. Finally, newer studies support previous evidence that ebastine has modulating effects on the allergic inflammatory process in addition to its antihistamine effects, which may help explain the beneficial effect that ebastine has on nasal obstruction in some patients. No new tolerability/safety signals have emerged after broad-use experience worldwide.
In conclusion, ebastine is an effective and well-tolerated second-generation H 1 Table 3 . Randomised, double-blind, controlled trials evaluating the efficacy of ebastine in adults and adolescents with seasonal allergic rhinitis Table 4 . Randomised, double-blind, controlled trials evaluating the efficacy of ebastine in adults and adolescents with perennial allergic rhinitis Table 5 . Clinical trials evaluating the efficacy of ebastine in adults with urticaria Table 6 . Long-term efficacy of ebastine in patients with chronic urticaria: results from a 12month non-comparative evaluation of the safety and tolerability of ebastine 10 mg in Europe Ebastine ≥10 mg reduced histamine-induced cutaneous wheal response versus placebo in healthy adults and adults with allergic rhinitis (p<0.05) [22] [23] [24] [25] [26] [27] [28] [29] .
After single doses of ebastine 1-30 mg, peak inhibition of wheals occurred 2-12 hours after intradermal histamine challenge; dosedependent effect; after 24 hours, wheals remained reduced by 50% with ebastine 10 mg versus placebo [27, 28] .
Inhibitory effect of ebastine on wheal/flare responses disappeared by 5 days after stopping administration [30] .
Ebastine 10 mg as effective as cetirizine 10 mg, fexofenadine 120 mg, loratadine 10 mg and mizolastine 10 mg at inhibiting histamine-induced wheal response [25, 29] . Ebastine 20 mg more effective (p<0.05) than cetirizine, loratadine and fexofenadine at 24 hours after dosing [22, 25, 26] . Results for flare response after cutaneous histamine challenge generally consistent with those for wheal response [22, 26, 31] .
Ebastine fast-dissolving tablet 10 mg and 20 mg more effective than desloratadine 5 mg at inhibiting the histamine-induced wheal response at 24 hours after dosing (p<0.001) [23, 24] .
Ebastine 10 and 30 mg reduced histamine-induced bronchoconstriction versus placebo in patients with asthma; no dose-response relationship [32] .
Antiallergy effects
In patients with animal/plant allergies, wheal and flare responses to cutaneous allergen challenge reduced significantly (p<0.01) by ebastine 20 mg versus placebo at 6, 24 and 48 hours after completing 1 week of treatment [30] .
In patients with grass pollen allergy, ebastine 10 mg reduced pollen-induced wheal diameter significantly versus placebo (p=0.013) and to a similar extent to cetirizine 10 mg, fexofenadine 120 mg, loratadine 10 mg and mizolastine 10 mg [29] . All antihistamines reduced nasal blockage and sneezing (but not rhinorrhoea) versus placebo at 4 hours after nasal provocation with pollen (p<0.05) [29] .
In patients with grass pollen allergy, mean number of pollen grains needed to induce an allergic response after nasal provocation was higher in recipients of ebastine 10 or 20 mg versus placebo (p<0.05) [33] .
Effects on other mediators of inflammation
In nasal polyp cells in vitro, ebastine inhibited anti-IgE-induced release of prostaglandin D 2 (PGD2) and leukotrienes C 4 /D 4 (LTC 4 /D 4 ) (p<0.05). It also inhibited granulocyte-macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor-α and interleukin-8 release [33] . Carebastine had a smaller effect than ebastine.
In patients with grass pollen allergy, ebastine 10 and 20 mg reduced the release of GM-CSF (but not PGD2, LTC 4 /D 4 or other cytokines) in nasal secretions in a dose-dependent manner [33] .
In patients with grass pollen allergy, a smaller increase in nasal eosinophilia was seen after treatment with ebastine 10 mg versus placebo (p=0.004); effect was similar to that seen with cetirizine, fexofenadine, loratadine and mizolastine [29] .
In patients with bronchial asthma, ebastine 10 mg reduced peripheral blood eosinophil count (p<0.0253) and serum eosinophil cationic protein level (p<0.0014) in atopic, but not non-atopic, patients [34] .
In patients with persistent allergic rhinitis, ebastine increased interferon-γ production by peripheral blood mononuclear cells in response to stimulation by grasses (p<0.0001) or house-dust mite Dermatophagoides farinae (p=0.0015) [35] .
Ebastine demonstrated potent anti-angiogenic activity in in vitro (human umbilical vein endothelial cell and human pulmonary artery cell) assays (p≤0.03) and an in vivo (chick embryo chorioallantoic membrane) assay p<0.001) [36] . Placebo Ebastine more efficacious than placebo for relief of nasal symptoms (p<0.05) but not ocular symptoms.
Global efficacy rated good/very good by more patients and physicians for ebastine than placebo (patients 84% vs 40%; physicians:
79% vs 35%; overall p<0.01).
[55]
(2 weeks) 116 Ebastine 10 mg Placebo Ebastine 10 mg more efficacious than placebo for relief of nasal symptoms such as rhinorrhoea (p=0.003) and sneezing (p-0.008) (but not nasal obstruction) and ocular symptoms such as tears and conjunctival irritation (p values not reported).
Ebastine 10 mg more efficacious than placebo based on physician global efficacy rating of good/excellent (56% vs 46%, p=0.008).
[56] Ebastine 10 and 20 mg more efficacious than placebo based on patient (p<0.05) and physician (p<0.01) global efficacy rating. More patients and physicians rated ebastine 10 and 20 mg as "efficacious" (i.e. moderate/ good/excellent) than rated placebo as such (patients 61% vs 66% vs placebo 36%; physicians: 72% vs 64% vs placebo 33%).
No significant differences between ebastine 10 and 20 mg. No significant difference in change in total symptom score between groups at study end. Greater reduction in total symptom score with ebastine 20 mg vs ebastine 10 mg and cetirizine 10 mg after 1 week (p<0.05). In a subgroup with more severe baseline symptoms (n=158), greater reduction in total symptom score at study end with ebastine 20 mg vs ebastine 10 mg (p=0.027) but not vs cetirizine 10 mg.
Physician (but not patient) global efficacy ratings better for ebastine 20 mg (but not 10 mg) vs cetirizine 10 mg (improvement in 85% vs 73%; p=0.048).
[59] Patient and physician global ratings not significantly different vs placebo for any active treatment.
Reductions in reflective nasal index scores with/without congestion (but not in reflective total symptom score with/without congestion) and in all four snapshot composite scores were greater with ebastine 20 mg vs loratadine 10 mg (p<0.05). No significant differences between ebastine 10 mg vs loratadine 10 mg for any composite scores.
No significant difference for ebastine 10 or 20 mg vs loratadine for patient or physician global ratings. Greater reduction in all four mean daily reflective composite scores (total symptom score with/without congestion and nasal index with/without congestion), all four-morning snapshot composite scores and most individual scores with ebastine 20 mg vs loratadine 10 mg (p<0.05). No significant difference between ebastine 10 mg vs loratadine 10 mg.
Patient and physician global ratings did not differ significantly between active treatments. More patients and physicians rated condition as somewhat/greatly improved with ebastine 10 mg (72-80%) and 20 mg (84%) than with placebo (58%) (p<0.02).
No significant differences between ebastine 10 and 20 mg. More cetirizine recipients had reduced nasal congestion (p<0.04) and were symptom-free (p=0.02) at study end. 
No significant differences between ebastine doses.
Condition rated as improved by more patients and physicians for ebastine 10 and 20 mg (79-85%) vs loratadine 10 mg (65-66%) (p<0.05).
Efficacy was generally based on evaluation of nasal symptoms (rhinorrhoea, sneezing, itching, obstruction) and ocular symptoms (e.g. itch, discharge, conjunctivitis). Symptoms were assessed individually and/or as composite scores, such as total symptom score, nasal index (composite of four nasal symptoms) or perennial index (nasal symptoms excluding obstruction). Symptoms were usually rated on a graded scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). In some trials, patients recorded symptom scores twice daily, based on their symptoms over the previous 12 hours (reflective score) and at the time of recording (snapshot score). Longitudinal study in acute urticaria [82] (4 weeks)
150
Ebastine 20 mg Ebastine 10 mg Levocetirizine 5 mg After 4 weeks the mean urticaria activity score was 1.08 for ebastine 20 mg, 1.98 for levocetirizine and 3.98 for ebastine 10 mg. in these 3 groups the percentage of patients with symptom relief were 80%, 70% and 50%, respectively.
Double-blind crossover study in dermographic urticaria: pilot study [83] (single-dose) 7 Ebastine 20 mg
Placebo
Ebastine prevented signs and symptoms of urticaria resulting from mechanical challenge. Of 7 patients with dermographic urticaria, all continued to experience wheals with placebo, but only 2 had wheals after ebastine.
Double-blind crossover study in acquired cold urticaria: pilot study [84] (single-dose) 22 Ebastine 20 mg
Ebastine was significantly superior to placebo in terms of reducing the number of patients with wheals (p<0.001), pruritus (p<0.001) and experiencing a burning sensation (p<0.05).
*Terfenadine administered as 60 mg twice daily. Terfenadine is no longer marketed.
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